<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2007-10-21" updated="2020-01-02">
  <drugbank-id primary="true">DB04968</drugbank-id>
  <name>PH94B</name>
  <description>PH94B is being developed by Pherin Pharmaceuticals, Inc. for the treatment of social phobias (generalized anxiety disorder). It is a member of a new family of pharmaceutical compounds called vomeropherins.</description>
  <cas-number/>
  <unii/>
  <state>solid</state>
  <groups>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A3094</ref-id>
        <pubmed-id>7938363</pubmed-id>
        <citation>Monti-Bloch L, Jennings-White C, Dolberg DS, Berliner DL: The human vomeronasal system. Psychoneuroendocrinology. 1994;19(5-7):673-86.</citation>
      </article>
    </articles>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication>Intended for the acute treatment of social phobia.</indication>
  <pharmacodynamics>Vomeropherin compounds are directly delivered to the nasal passages using either a metered nasal spray or a metered nasal aerosol. By virtue of the chemoreceptorâ€™s location in the nasal passages, direct connections to the hypothalamus and limbic system and the ability of our compounds to act locally, vomeropherins do not need to achieve systemic absorption and distribution. This provides a significant therapeutic advantage over traditional therapeutics targeted at the hypothalamus and limbic system that require access to systemic circulation and must cross the blood-brain barrier followed by uptake into the brain to exert effects.</pharmacodynamics>
  <mechanism-of-action>There is little information available on the mechanism of action of vomeropherins. These compounds are delivered to the nasal passages and bind to chemoreceptors that in turn affect the hypothalamus and the limbic system.</mechanism-of-action>
  <toxicity/>
  <metabolism/>
  <absorption>Absorbed following nasal administration.</absorption>
  <half-life/>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution/>
  <clearance/>
  <salts/>
  <synonyms/>
  <products/>
  <international-brands/>
  <mixtures/>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories/>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages/>
  <atc-codes/>
  <ahfs-codes/>
  <pdb-entries/>
  <patents/>
  <food-interactions/>
  <drug-interactions/>
  <calculated-properties/>
  <experimental-properties/>
  <external-identifiers>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>347909864</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>PH94B</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets/>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>